Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life st...
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA). However, few studies on the efficacy of this biologic in real life are available. The aim was to elucidate the efficac...
Alternative Titles
Full title
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dad4c27f3770442ba57c71cc9b082581
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dad4c27f3770442ba57c71cc9b082581
Other Identifiers
ISSN
1471-2466
E-ISSN
1471-2466
DOI
10.1186/s12890-020-01248-x
